Abstract
Background Coronavirus disease 2019 (COVID-19), may progress to respiratory failure requiring invasive mechanical ventilation. Due to ventilator shortage and healthcare systems strain, affordable interventions such as awake prone positioning has been used to improve oxygenation, however, the effect of this intervention on patient-important outcomes is uncertain. The COVI-PRONE trial aims to determine if awake prone positioning in hypoxemic COVID-19 patients reduces the need for invasive mechanical ventilation.
Study design A pragmatic, multicenter, international, parallel-group, and stratified randomized controlled trial, aiming to enrol 400 hospitalized adults with COVID-19.
Participants The target population is hospitalized adults with confirmed or suspected COVID-19, hypoxemia that requires ≥40% oxygen or ≥ 5 L/min by nasal cannula, and abnormal chest x-ray. We will exclude patients with any of the following: immediate need for intubation; altered mental status; contraindication to prone positioning; hemodynamic instability; body mass index > 40 kg/m2; third trimester pregnancy; do not intubate status; previous enrolment or intubation within the same hospital admission; and prone positioning for more than one day prior to randomization.
Study intervention and control Following informed a priori or deferred consent, eligible patients will be centrally randomized to either the intervention arm (prone positioning) or standard of care (no prone positioning). Patients randomized to the prone position will be required to either self-prone or assist-prone for a total of eight to ten hours per day until they meet pre-specified stopping criteria.
Study outcomes The primary outcome is invasive mechanical ventilation at 30-days of randomization. Other outcomes include mortality at 60 days, invasive and non-invasive mechanical ventilation free days at 30 days, hospital length of stay at 60 days, days alive and outside of the hospital at 60 days, complications of proning, and serious adverse events.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04350723
Funding Statement
The trial received funding from the Canadian Institute of Health Research (CIHR), McMaster University, Hamilton, Canada, and King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Clinical Trials Ontario ethics committee (reference number 2154), as well as the respective ethics boards of participating centres not governed by CLinical Trial Ontario, as per the list below. The list of regulatory bodies that have approved the study conduct: 1) Clinical Trials Ontario (Canada), all Ontario Sites Clinical Trials Ontario Project ID 2154 2) The Conjoint Health Research Ethics Board (Canada), all Calgary Sites REB 20-0731 3) State of Kuwait Ministry of Health, Assistant Undersecretary for Planning & Quality (Kuwait), both Sites Study No. 1526/2020 4) The Research Ethics Board (REB) of the Centre Hospitalier Universitaire de Quebec, Universite Laval (Canada), Quebec MP-20-2021-5459 5) King Abdullah International Research Center (Saudi Arabia), sites 176, 177, 185, and 211 IRBC/0823/21 6) King Abdullah International Research Center (Saudi Arabia), site 185 IRBC/ 1181/20 7) Imam Abdulrahman Bin Faisal University Institutional Review Board (Saudi Arabia), site 178 IRB-2020-01-180 8) Committee of the Protection of Human Subjects (USA), Texas HSC-MS-20-0793 9) King Faisal Specialist Hospital and Research Centre, Research Ethics Committee (Saudi Arabia), RAC 2201114
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
not applicable
